Thursday 31 October


Friday 1 November

Behind the headlines: Therapeutics development from academic lab, to spin out and exit

Dr Anne-Laure Puaux, Head of Business Development & CEO, WEHI Ventures

The potential of emerging non-animal models for medical product development

Dr Kim Fung, Principal Research Scientist, CSIRO

Practical & legal considerations of deploying AI in the biotech sector - now and future

David Hansen, Chief Executive Officer & Research Director, Australian e-Health Research, CSIRO

Synergy in science: Integrating AI, robotics and quantum computing for drug discovery

Dr Robert Marino, Chief Executive Officer, Qubit Pharmaceuticals

Cell & Gene Summit

A holistic approach to cell & gene therapies is crucial for the life science industry

Abhi Gupta, Senior Vice President & Head of Cell & Gene Therapy, Syneos Health

Streamlining market access to advanced therapies: What can we learn from global models?

Warwick Shaw, Market Access Cell & Gene Therapies and Medicines Australia Rare Diseases Working Group, Johnson & Johnson

Commercialisation of cell and gene therapies: What does it take

Sam Cobb, Chief Executive Officer, Currus

Dr Cameron Smith, Partner, FB Rice

Ethical access and emerging technologies in cell and gene therapies

Prof Christine Wells, Chair, Stem Cell Systems, The University of Melbourne